In this study, only the change rule of STM in HER2-negative breast cancer was investigated, because patients with HER2-positive breast cancer will not only receive chemotherapy but also receive targeted therapy, with many influencing factors, so it was not included in this study population. The gene discussed is ERBB2; the disease is breast carcinoma.